NewslettersCell Therapy NewsUncategorizedMultiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B Cell Malignancy PatientsBy Justin.choi - December 10, 20210263The authors developed an anti-CD19 CAR comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.[Nature Communications] 6445212 AAAAAAAA items 1 apa 0 default asc 1 169928 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Full Article